Date: 2013-07-16
Type of information: R&D agreement
Compound: medicinal chemistry and computer-aided drug design services
Company: Argenta (Galapagos subsidiary – UK Belgium) Pcovery (Denmark)
Therapeutic area: Infectious diseases
Type agreement: R&D
collaboration
Action mechanism:
Disease: fungal infections
Details: * On July 16, 2013, Argenta, a Galapagos company that provides drug discovery services from target validation to proof of concept, has announced that it has signed a collaboration agreement with Pcovery. Under the terms of the agreement, Argenta will provide medicinal chemistry and computer-aided drug design services, together with its integrated drug discovery expertise, to assist Pcovery in the identification of novel anti-fungal agents with the aim of discovering a development candidate that can be progressed into clinical trials. The collaboration is funded by a Wellcome Trust Seeding Drug Discovery (SDD) award.
Pcovery is focused on the development of safe and efficient broad-spectrum anti-fungal agents using structure-based drug discovery to target membrane proteins. Pcovery is a spin-out company from the PUMPkin Centre (Centre for Membrane Pumps in Cells and Disease) at Aarhus University and Copenhagen University and was established in April 2009. The company’s investors include Novo Seeds and Østjysk Innovation.
Financial terms:
Latest news:
